GlobeNewswire

Cisco Launches New '5G Now' Portfolio for Service Providers Taking Action Today

Dela

More than 20 global service provider and mobile operator customers worldwide are advancing their 5G action plans with Cisco

BARCELONA, Spain, Feb. 25, 2018 (GLOBE NEWSWIRE) -- Mobile World Congress - Continuing on its path to disrupt the industry by redefining the network, Cisco announced today its '5G Now' portfolio for service providers ready to go full throttle on their 5G roadmap.  

5G services promise to offer emerging new services at significantly faster speeds, expanded capacity and stronger coverage to accommodate the more than 27 billion connected devices1 expected on service provider networks by 2021. Beginning 2020, 5G connections will grow more than a thousand percent from 2.3 million in 2020 to over 25 million in 20212

At Mobile World Congress this week, many technology vendors are focused on the spectrum advantages, radio equipment and architecture to support 5G services. Cisco is committed to showing service providers and mobile operators why 5G is important to plan for, and what they can really do with it. Cisco's role here is focused on three things:   

  1. Services: Planning for new 5G-enabled services Cisco can help deliver
  2. Infrastructure: Mapping the right 5G infrastructure to their needs
  3. Automation: Helping to make the mass network scaling for 5G simpler to manage, operate and secure

Cisco uniquely offers its customers a cloud-to-client approach for 5G networking, resulting from its investments and commitment to developing cloud applications and services, to help customers unify multi-vendor solutions into a single, standards-based architecture. Key elements in the Cisco '5G Now' portfolio include:

  • Multi-cloud: Helping manage workloads across a full ecosystem of private, public, and hybrid clouds to connect enterprise, consumers, and service providers.

  • IP Core: Cisco can expand programmability and capabilities of the network with real-time telemetry for automation, featuring the new Cisco NCS-500 Series of access routers with the Cisco IOS XR software as a single domain from the data center to the cell tower.

  • 5G Packet Core and Service Edge: With Cisco Ultra, its cloud-native, mobile virtualized packet core, Cisco provides a unified platform for service enablement over licensed and unlicensed radio solutions and IoT services - all the way to the network edge.

  • Access: Cisco offers a comprehensive solution that unifies cable, fiber, Wi-Fi, and a variety of licensed radio solutions including virtualized RAN architectures such as Open RAN. The new Cisco SONFlex Studio features drag-and-drop ease to create new self-organizing network (SON) APIs to customize service handling and quality of experience in the radio access network.

  • Client Services: This is where the cloud meets the customer. Cisco will be demonstrating a number of client services that can be delivered today including Managed Cisco Spark for collaboration service over mobile, virtual managed services for cloud-based SD-WAN business services, and the Cisco Jasper platform for IoT.

  • Security: Cisco secures the Service Provider from the cloud, to the network, to the client with its new 5G Security Architecture that builds upon the comprehensive portfolio of threat-centric solutions to securely enable 5G mobile networks. New offers include Stealthwatch for enhanced breach detection and visibility within Evolved Packet Core (EPC) and network slices, Stealthwatch Cloud for cloud-managed network security, and the Cisco Umbrella Security Suite.
     
  • Professional Services: Cisco takes an open approach to partnering and co-developing with its customers to fit the right solution, offering experienced personnel to support the customers' teams from start to finish.

Cisco's '5G Now' demonstrations are available at the Cisco booth in Hall 3 Hybrid Hall, #3E30.

More than 20 global service provider and mobile operator customers worldwide are advancing their 5G action plans with Cisco including Saudi Telecom Company (STC) and many others.

"STC is working closely with Cisco as a key technology partner to drive innovation for the future of Saudi Arabia communications," said Eng. Nasser Al Nasser, chief operations officer, STC. "We are aligned with the Kingdom's Vision 2030 for a digital society that fosters growth in Saudi Arabia's economy. Our plans to advance our communications infrastructure with programmability and automation will support a host of new services enabled by 5G spanning education, enterprise, health, IoT, recreation and tourism."

"4G was about buying connectivity, and 5G is about buying experiences,"  said   Yvette Kanouff, senior vice president, general manager, Service Provider Business,   Cisco.  "5G creates a new environment for service creation, giving operators what they need to deliver next-level entertainment experiences. Only Cisco has the services, infrastructure and automation portfolio to support our global customers with their 5G initiatives."  

Cisco is leading the disruption in the industry with our technology innovations in systems, silicon, optics and security, and our unrivalled expertise in mass-scale networking, automation, optical, cable access, video, and mobility. Together with our portfolio of professional services, we can enable service providers and media and web companies to reduce cost and complexity, help secure their networks and grow revenue. 

Supporting Resources

RSS Feed for Cisco:  http://newsroom.cisco.com/dlls/rss.html

About Cisco 
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

PR Contact: Sara Cicero, stutzes@cisco.com, 770-331-0269.

1 Cisco Visual Networking Index Forecast (VNI), 2016-2021

2 Cisco VNI Mobile 2017




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum